Recursion Pharmaceuticals is a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.
Recursion’s CEO and President is Najat Khan, Ph.D.
Recursion was founded by Blake Borgeson, Ph.D., Chris Gibson, Ph.D., and Dean Li, M.D., Ph.D.
November 5, 2013
Recursion’s mission is to decode biology to radically improve lives.
Salt Lake City, Utah
Recursion’s clinical stage programs span oncology and rare disease:
For more detailed information on each program, please visit our pipeline page.
Information on ongoing Recursion clinical trials and their locations can be found on our clinical trials page and clinicaltrials.gov
Yes - Recursion focuses on diseases where there is a high unmet need, including rare diseases and oncology. For rare diseases, Recursion has a clinical-stage program in familial adenomatous polyposis (FAP) and a preclinical stage program in hypophosphatasia.
Yes - Recursion focuses on diseases where there is a high unmet need, including oncology and rare diseases. Recursion has multiple clinical stage and preclinical stage oncology programs ongoing, across solid tumors and blood cancers.
Yes - alongside our fully owned portfolio, we partner with leading biopharmaceutical companies to discover and develop potential new medicines in oncology as well as neuroscience, immunology, and other therapeutic areas with high unmet need.
Recursion collaborates with leading biopharmaceutical and technology companies to broadly explore diverse disease domains and rapidly identify novel therapeutic candidates via AI. Our partners fit into two main categories:
Therapeutic Partners:
Data, Technology, and Capability Partners:
Recursion’s AI-native product engine is an end-to-end continuous learning system for drug discovery and development. It seamlessly connects physical experimentation in our automated wet labs with computational analysis powered by supercomputing and foundation models.
By operating as a closed loop, with every lab experiment strengthening our AI models, every model informing the next experiment, and every cycle deepening our understanding of human biology, the engine systematically maps disease biology, precision-designs differentiated molecules, and optimizes clinical development to bring better medicines to patients faster.

Watch our Video to Learn More About Recursion’s AI-Native Product Engine
Recursion’s core competitive advantage lies in our end-to-end, AI-native continuous learning system. Unlike competitors that rely on single-point tools or traditional hypothesis-driven research, our integrated platform connects automated data generation, supercomputing, generative chemistry, and clinical development into one closed loop. This closed-loop system turns drug discovery and development into a repeatable, data-driven process, allowing us to consistently translate complex science into clinical-stage investigational medicines at a fraction of traditional timelines.
Watch Recursion’s CEO Najat Khan discuss her vision for AI translation and platform progress.
Recursion employs an AI-native strategy, replacing slow, manual, hypothesis-driven research. We use our integrated, end-to-end engine—which connects automated AI-native data factories and supercompute-powered AI/machine learning foundation models—to rapidly and in an unbiased manner discover potential new medicines at an unprecedented scale, achieving speeds up to 3X faster than traditional industry averages.
Recursion applies AI/ML across the entire drug discovery and development workflow through three core interconnected pillars:
This capabilities stack is powered by three core pillars of infrastructure:
Maps of Biology are comprehensive, searchable digital representations of human biological systems created by our AI-native Data Factories.
Instead of relying on single, narrow hypotheses, Recursion builds these high-dimensional maps at an unprecedented scale:
By comparing the fingerprints of disease-causing mutations against millions of other genetic manipulations on our maps, our AI models identify non-obvious genetic perturbations that mimic or rescue disease states. This uncovers novel, causal biological targets and pathways beyond traditional research—which are then sent directly back to our labs for experimental validation.
Because this high-dimensional data is so rich, our maps of biology are reusable, allowing us to re-mine the same datasets to generate multiple hypotheses across programs over time.
Recursion transforms chemical design from a slow, trial-and-error process into an automated, closed-loop engineering discipline. By unifying computational molecular design with automated wet-lab synthesis and testing into an integrated Design-Make-Test-Learn (DMTL) cycle, we eliminate the traditional disconnect between prediction and physical chemistry.
Through our design engine, we evaluate complex multi-parameter profiles simultaneously—balancing potency, ADME properties, 3D binding structures, toxicity, and synthesis feasibility using predictive machine learning models. Our computational algorithms prioritize structures that are synthetically accessible before sending them to the lab, ensuring chemistry resources focus only on molecules with high likelihoods of success. These designs flow directly into automated synthesis platforms and testing assays with digital tracking across every reaction step. Because every physical test result immediately feeds back into our computational models, the underlying predictive system continuously sharpens its calculations for subsequent iterations.
This integration accelerates timelines, cutting time to delivering a candidate down from an industry benchmark of roughly 42 months to approximately 17 months. By coupling synthesis-aware computation with data-driven physical testing, Recursion reaches quality clinical-stage candidates after synthesizing only around 300 physical compounds. This represents roughly 90% fewer molecules than the traditional pharmaceutical industry average of ~5,000 compounds per program.
ClinTech is Recursion's approach to applying AI and technology across clinical research, extending our industrialized platform beyond initial discovery and directly into human trials. The strategy is built on three key pillars:
This overall approach aims to improve the speed and efficiency of bringing new therapies to patients.
Yes. Recursion is committed to advancing science through open-sourcing data and models for non-commercial use. Our current public offerings include:
You can explore Recursion’s open source data and models at rxrx.ai
TechBio is an evolution of the life sciences focused on leveraging advanced technologies like artificial intelligence, machine learning, engineering and automation to understand biology at a systems level to discover new medicines. It relies on the creation of large, robust, highly structured biological and chemical datasets to fuel advanced computational models that can reveal subtle patterns that humans alone might miss. TechBio companies have data, compute and AI models at their core, enabling a new era of data-driven and unbiased drug discovery.
We believe TechBio companies will create step-function shifts in the healthcare industry. Recursion is both leading this new sector, and working hard to help define it.
The difference lies in the strategic starting point and technological core. Traditional biotech begins with a therapeutic hypothesis developed around a simplified view of disease biology, relying on serial, human-intensive lab work. TechBio, conversely, starts with massive, scaled data generation and supercomputing power to train AI models and identify patterns humans can’t see. This industrialized approach enables companies like Recursion to move beyond limited hypotheses and understand complex biology at a systems level, leading to data-driven, unbiased drug discovery with vastly accelerated speed and scale.
Phenomics measures the morphology (shape and structure) of cultured cells grown in laboratory plates. Morphology is a holistic readout that integrates changes from underlying layers of cell biology—such as gene expression and protein modification—into a single, powerful measure of cellular state.
Phenomics forms the backbone of Recursion’s Maps of Biology by enabling the platform to:
Transcriptomics is a high-dimensional measure of cellular biology, distinct from phenomics, that assesses gene expression by measuring RNA levels in the cell.
As a crucial complementary data layer, Recursion uses high-throughput transcriptomics platforms to generate massive amounts of data on chemically or genetically perturbed cells. This non-image-based data is combined with other modalities to: